A revolutionary frontier is emerging in the battle against neurodegenerative diseases, driven by the versatile and powerful approach of Chimeric Antigen Receptor (CAR) immunotherapies. Researchers at the Universitat Autònoma de Barcelona (UAB) have taken a critical step forward by defining the foundational principles that these therapies must embody to transition from conceptual frameworks to tangible clinical advancements. Their insights were recently presented in a comprehensive review published in Trends in Pharmacological Sciences, articulating the immense promise and complex challenges of applying CAR technology, historically successful in cancer, to the intricate landscape of neurodegeneration.
The hallmark of CAR immunotherapy lies in its capacity for customization: immune cells, harvested from patients, are genetically engineered to express synthetic receptors—CARs—on their surfaces. These receptors are designed to recognize and bind specific pathogenic molecules, such as aberrant protein aggregates implicated in diseases like Alzheimer’s and Parkinson’s. This binding not only marks the target for destruction but also activates the immune cell to mount a precise immune response. However, the application of this paradigm to neurodegenerative proteinopathies is fraught with unprecedented complexity.
Unlike cancer, where targets are often well-defined and relatively stable, neurodegenerative disorders present a dynamic and heterogeneous set of molecular challenges. The pathogenic proteins involved exist in various conformations and aggregation states, evolving spatially across different brain regions and temporally throughout disease progression. This heterogeneity demands immunotherapeutic devices capable not just of elimination but of adaptable modulation, shifting therapeutic objectives from outright eradication of pathological proteins to carefully calibrated control over their pathological effects.
At the heart of the UAB team’s proposition is a set of core requirements for CAR therapies in the neurodegenerative context: high selectivity, programmability, sustained activity, and controllability. High selective precision is paramount to differentiate between pathogenic aggregates and their non-toxic or functional counterparts, thereby minimizing collateral damage within the sensitive neural environment. Programmability refers to the ability to modify and fine-tune CAR constructs and effector cell behaviors in response to disease stage or molecular milieu changes. Sustained activity ensures long-term therapeutic effects essential for chronic neurodegenerative conditions, while precise controllability offers mechanisms to turn therapy on or off, preventing overactivation-associated toxicity.
The choice of effector immune cells represents a major paradigm shift recommended by the researchers. While CAR-T lymphocytes have revolutionized hematological oncology, their applicability to neurodegeneration is limited. Instead, microglia, macrophages, and regulatory T cells (Tregs) emerge as promising candidates. These cells naturally participate in CNS homeostasis and immune regulation, and their functions align well with the multifactorial and often chronic nature of neurodegenerative pathology. Microglia and macrophages could be harnessed for early-stage interventions aimed at phagocytosing toxic aggregates, thereby limiting spread and injury, whereas Tregs might play pivotal roles in later-stage immunomodulation, suppressing excessive inflammatory responses known to exacerbate neuronal damage.
A particularly profound challenge in this arena concerns the delicate balance of activating an immune response without triggering harmful neuroinflammation. The brain’s low tolerance for inflammation, coupled with the irreversible nature of neuronal loss, necessitates sophisticated switchable CAR platforms. Inspired by Boolean logic frameworks, researchers are exploring designs incorporating logical AND, OR, and NOT gates within CAR architectures. Such logic-gated systems would enable conditional activation depending on the presence of multiple disease markers or contextual cues, greatly enhancing both specificity and safety.
Moreover, the cellular platforms are envisioned to embed on-off control features alongside conditional secretion of immunoregulatory molecules. This allows the engineered immune cells not only to clear toxic aggregates but also to dynamically modulate the CNS inflammatory milieu, thus preventing secondary damage and improving the overall neuroimmune balance. Although still largely conceptual, such architectural advances in synthetic receptor design represent a critical step towards robust, adaptable, and safe clinical therapies.
The UAB research group also highlighted the importance of molecular precision in receptor design. Enhancing the binding affinity and selectivity of CARs to pathogenic aggregates is central to therapeutic efficacy but is complicated by the molecular diversity of aggregated proteins. This underscores the need for advanced bioengineering techniques, including computational modeling and high-throughput screening, to optimize receptor constructs capable of discriminating subtle structural variants of aggregates while sparing physiological protein forms.
Research into stage-specific immunotherapeutic strategies further refines the envisioned therapeutic roadmap. Early disease phases targeted with macrophage and microglia-based CAR therapies would focus on the clearance of aggregates, aiming to slow or halt disease progression by tackling the root pathological drivers before irreversible damage occurs. In contrast, in middle and late stages, immune regulation becomes paramount to alleviate chronic inflammation, a key mediator of neurodegeneration progression. Here, Treg-based CAR platforms could provide the necessary immunosuppressive control, mitigating neurotoxic innate immune activation.
For terminal stages, when aggregate clearance is insufficient, multifunctional CAR platforms that combine effector functions with switches controlling secretion of anti-inflammatory cytokines or factors promoting neuronal survival might be essential. This sophistication could transform neurodegenerative disease treatment into a dynamic, multi-layered immunotherapeutic intervention adjustable in real-time according to disease evolution and patient-specific pathology.
Although existing clinical data remain in their infancy—largely confined to in vitro and animal models—the conceptual advancements put forth by the UAB team invigorate the field. The emerging proof-of-concept studies, including innovative astrocyte-based CAR therapies, suggest newfound accessibility to CNS processes previously deemed therapeutically elusive. As these sophisticated immune engineering strategies evolve, they promise to break the stalemate of conventional neurodegeneration therapeutics, limited by the blood-brain barrier and the complexity of targets.
The potential of CAR immunotherapies to afford durable and customizable interventions heralds a paradigm shift with profound implications. Success in this domain could not only supply desperately needed disease-modifying therapies for devastating disorders like Alzheimer’s and Parkinson’s but also pave the way for tackling other central nervous system diseases marked by proteinopathies and immune dysregulation. Advancing this frontier relies heavily on integrating molecular biology, immunology, synthetic biology, and computational modeling to refine CAR architectures and ensure rigorous safety control.
In sum, the journey from CAR-T cell therapies in oncology to programmable CAR immunotherapies for neurodegenerative proteinopathies embodies a frontier full of challenges and opportunities. The multidisciplinary framework proposed by the UAB researchers, underscored by cellular specificity, precision engineering, logic-gated control systems, and adaptive immunomodulation, sets a strategic roadmap for bringing these advanced therapeutic platforms closer to clinical translation. As the scientific community continues to unravel the molecular and cellular puzzles of neurodegeneration, programmable CAR therapies may soon redefine the therapeutic landscape for some of the most intractable brain diseases of our time.
Subject of Research: Not applicable
Article Title: Programmable CAR immunotherapies for neurodegenerative proteinopathies
News Publication Date: 1-Apr-2026
Web References: http://dx.doi.org/10.1016/j.tips.2026.02.009
Image Credits: © IBB-UAB
Keywords: Neuroscience, Biochemistry, Bioinformatics, Immunotherapy, Alzheimer disease, Parkinsons disease
Tags: advances in Parkinson’s disease immunotherapyCAR immunotherapy for neurodegenerationchimeric antigen receptor therapies in Alzheimer’sclinical translation of CAR therapiesimmune cell engineering for brain diseasesimmune response modulation in neurodegenerative disordersneurodegenerative proteinopathy targetingnovel solutions in neurodegenerative disease treatmentovercoming challenges in CAR-T treatmentspersonalized immunotherapy for brain diseasessynthetic receptor design for neurodegenerationUniversitat Autònoma de Barcelona CAR research
